{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:52:09Z","timestamp":1776757929158,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sail Bio, Inc.","award":["P0270000"],"award-info":[{"award-number":["P0270000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10928-025-09989-0","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T19:28:09Z","timestamp":1753385289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying clinical and genetic factors influencing rate and severity of autosomal dominant tubulointerstitial kidney disease progression"],"prefix":"10.1007","volume":"52","author":[{"given":"Shyam S.","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7632-5851","authenticated-orcid":false,"given":"Mark","family":"Rogge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-0949","authenticated-orcid":false,"given":"Kendrah O.","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne H.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok Yong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Roignot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Blakeslee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Sr.","given":"Anthony J.","family":"Bleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-0735","authenticated-orcid":false,"given":"Sarah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"1","key":"9989_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12882-018-1107-y","volume":"19","author":"C Gast","year":"2018","unstructured":"Gast C, Marinaki A, Arenas-Hernandez M, Campbell S, Seaby EG, Pengelly RJ et al (2018) Autosomal dominant tubulointerstitial kidney disease-UMOD is the most frequent non polycystic genetic kidney disease. BMC Nephrol 19(1):301","journal-title":"BMC Nephrol"},{"issue":"2","key":"9989_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1806891","volume":"380","author":"EE Groopman","year":"2019","unstructured":"Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H et al (2019) Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 380(2):142\u2013151","journal-title":"N Engl J Med"},{"issue":"1","key":"9989_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41572-019-0109-9","volume":"5","author":"O Devuyst","year":"2019","unstructured":"Devuyst O, Olinger E, Weber S, Eckardt KU, Kmoch S, Rampoldi L et al (2019) Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers 5(1):60","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"9989_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ki.2015.28","volume":"88","author":"KU Eckardt","year":"2015","unstructured":"Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K et al (2015) Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management\u2014A KDIGO consensus report. Kidney Int 88(4):676\u2013683","journal-title":"Kidney Int"},{"issue":"3","key":"9989_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.kint.2020.04.038","volume":"98","author":"E Olinger","year":"2020","unstructured":"Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C et al (2020) Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1. Kidney Int 98(3):717\u2013731","journal-title":"Kidney Int"},{"issue":"5","key":"9989_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00467-021-05118-4","volume":"37","author":"AJ Bleyer","year":"2022","unstructured":"Bleyer AJ, Wolf MT, Kidd KO, Zivna M, Kmoch S (2022) Autosomal dominant tubulointerstitial kidney disease: more than just HNF1\u03b2. Pediatr Nephrol 37(5):933\u2013946","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"9989_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2215\/CJN.06380613","volume":"9","author":"AJ Bleyer","year":"2014","unstructured":"Bleyer AJ, Kmoch S, Antignac C, Robins V, Kidd K, Kelsoe JR et al (2014) Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol 9(3):527\u2013535","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"9989_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.ajkd.2018.03.019","volume":"72","author":"N Ayasreh","year":"2018","unstructured":"Ayasreh N, Bullich G, Miquel R, Furlano M, Ruiz P, Lorente L et al (2018) Autosomal dominant tubulointerstitial kidney disease: clinical presentation of patients with ADTKD-UMOD and ADTKD-MUC1. Am J Kidney Dis 72(3):411\u2013418","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"9989_CR9","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1097\/01.ASN.0000092147.83480.B5","volume":"14","author":"K Dahan","year":"2003","unstructured":"Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, Poux JM et al (2003) A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 14(11):2883\u20132893","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"9989_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ki.2011.134","volume":"80","author":"L Rampoldi","year":"2011","unstructured":"Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O (2011) The rediscovery of uromodulin (Tamm\u2013Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80(4):338\u2013347","journal-title":"Kidney Int"},{"issue":"1","key":"9989_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2169\/internalmedicine.1342-22","volume":"63","author":"T Takata","year":"2024","unstructured":"Takata T, Isomoto H (2024) The versatile role of uromodulin in renal homeostasis and its relevance in chronic kidney disease. Intern Med 63(1):17\u201323","journal-title":"Intern Med"},{"issue":"9","key":"9989_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrneph.2017.101","volume":"13","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Olinger E, Rampoldi L (2017) Uromodulin: from physiology to rare and complex kidney disorders. Nat Rev Nephrol 13(9):525\u2013544","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"9989_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/ndt\/gfab268","volume":"38","author":"H Mabillard","year":"2023","unstructured":"Mabillard H, Sayer JA, Olinger E (2023) Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease. Nephrol Dial Transplant 38(2):271\u2013282","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"9989_CR14","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1681\/ASN.2018030245","volume":"29","author":"KX Knaup","year":"2018","unstructured":"Knaup KX, Hackenbeck T, Popp B, Stoeckert J, Wenzel A, B\u00fcttner-Herold M et al (2018) Biallelic expression of mucin-1 in autosomal dominant tubulointerstitial kidney disease: implications for nongenetic disease recognition. JASN 29(9):2298\u20132309","journal-title":"JASN"},{"issue":"9","key":"9989_CR15","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1681\/ASN.2018020180","volume":"29","author":"M \u017divn\u00e1","year":"2018","unstructured":"\u017divn\u00e1 M, Kidd K, P\u0159istoupilov\u00e1 A, Bare\u0161ov\u00e1 V, DeFelice M, Blumenstiel B et al (2018) Noninvasive immunohistochemical diagnosis and novel MUC1 mutations causing autosomal dominant tubulointerstitial kidney disease. JASN 29(9):2418\u20132431","journal-title":"JASN"},{"issue":"1","key":"9989_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ajhg.2016.05.028","volume":"99","author":"NA Bolar","year":"2016","unstructured":"Bolar NA, Golzio C, \u017divn\u00e1 M, Hayot G, Van Hemelrijk C, Schepers D et al (2016) Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. Am J Human Genet 99(1):174\u2013187","journal-title":"Am J Human Genet"},{"issue":"1","key":"9989_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME et al (2020) Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and european medicines agency. Am J Kidney Dis 75(1):84\u2013104","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"9989_CR18","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.ekir.2020.06.029","volume":"5","author":"K Kidd","year":"2020","unstructured":"Kidd K, Vyletal P, Schaeffer C, Olinger E, \u017divn\u00e1 M, Hoda\u0148ov\u00e1 K et al (2020) Genetic and clinical predictors of age of ESKD in individuals with autosomal dominant tubulointerstitial kidney disease due to UMOD mutations. Kidney Int Rep 5(9):1472\u201385","journal-title":"Kidney Int Rep"},{"issue":"4","key":"9989_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jmoldx.2016.03.003","volume":"18","author":"B Blumenstiel","year":"2016","unstructured":"Blumenstiel B, DeFelice M, Birsoy O, Bleyer AJ, Kmoch S, Carter TA et al (2016) Development and validation of a mass spectrometry-based assay for the molecular diagnosis of mucin-1 kidney disease. J Mol Diagn 18(4):566\u2013571","journal-title":"J Mol Diagn"},{"issue":"2","key":"9989_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381","journal-title":"J Biomed Inform"},{"key":"9989_CR21","doi-asserted-by":"publisher","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)\u00a0(2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612.\u00a0https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006. Erratum in: Ann Intern Med. 2011;155(6):408","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"issue":"5","key":"9989_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cpt.2489","volume":"112","author":"A Sharma","year":"2022","unstructured":"Sharma A, Sahasrabudhe V, Musib L, Zhang S, Younis I, Kanodia J (2022) Time to rethink the current paradigm for assessing kidney function in drug development and beyond. Clin Pharma and Therapeutics 112(5):946\u2013958","journal-title":"Clin Pharma and Therapeutics"},{"issue":"4","key":"9989_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM (2008) Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 35(4):401\u2013421","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"9989_CR24","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1038\/s41598-021-89442-7","volume":"11","author":"T Waas","year":"2021","unstructured":"Waas T, Schulz A, Lotz J, Rossmann H, Pfeiffer N, Beutel ME et al (2021) Distribution of estimated glomerular filtration rate and determinants of its age dependent loss in a German population-based study. Sci Rep 11(1):10165","journal-title":"Sci Rep"},{"issue":"3","key":"9989_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.kint.2017.03.013","volume":"92","author":"TL Tsai","year":"2017","unstructured":"Tsai TL, Kuo CC, Pan WH, Chung YT, Chen CY, Wu TN et al (2017) The decline in kidney function with chromium exposure is exacerbated with co-exposure to lead and cadmium. Kidney Int 92(3):710\u2013720","journal-title":"Kidney Int"},{"issue":"1","key":"9989_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12882-018-1126-8","volume":"19","author":"A Fenton","year":"2018","unstructured":"Fenton A, Montgomery E, Nightingale P, Peters AM, Sheerin N, Wroe AC et al (2018) Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation. BMC Nephrol 19(1):336","journal-title":"BMC Nephrol"},{"issue":"5","key":"9989_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.18","volume":"2","author":"N Holford","year":"2013","unstructured":"Holford N (2013) A time to event tutorial for pharmacometricians. CPT Pharmacom Syst Pharma 2(5):1\u20138","journal-title":"CPT Pharmacom Syst Pharma"},{"issue":"2","key":"9989_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1037\/a0027127","volume":"17","author":"SI Vrieze","year":"2012","unstructured":"Vrieze SI (2012) Model selection and psychological theory: A discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods 17(2):228\u2013243","journal-title":"Psychol Methods"},{"key":"9989_CR29","unstructured":"Introduction to Population Pharmacokinetic \/ Pharmacodynamic Analysis with Nonlinear Mixed Effects Models | Wiley Online Books [Internet]. [cited 2024 May 10]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781118784860.\u00a0Accessed 20 Aug 2024"},{"issue":"2","key":"9989_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151","journal-title":"AAPS J"},{"key":"9989_CR31","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2024 May 10]. Available from: https:\/\/www.r-project.org\/.\u00a0Accessed 10 Oct 2022"},{"issue":"7","key":"9989_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/psp4.12973","volume":"12","author":"JF Morales","year":"2023","unstructured":"Morales JF, Muse R, Podichetty JT, Burton J, David S, Lang P et al (2023) Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies. CPT Pharmacom Syst Pharma 12(7):1016\u20131028","journal-title":"CPT Pharmacom Syst Pharma"},{"issue":"10","key":"9989_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/psp4.13021","volume":"12","author":"S Kim","year":"2023","unstructured":"Kim S, Willcocks RJ, Daniels MJ, Morales JF, Yoon DY, Triplett WT et al (2023) Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials. CPT Pharmacom Syst Pharma 12(10):1437\u20131449","journal-title":"CPT Pharmacom Syst Pharma"},{"key":"9989_CR34","doi-asserted-by":"publisher","unstructured":"Yoon DY, Daniels MJ, Willcocks RJ, Triplett WT, Morales JF, Walter GA, Rooney WD, Vandenborne K, Kim S, DMD MR Biomarker Steering Committee (2024) Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles. J Pharmacokinet Pharmacodyn 51(6):671\u2013683. https:\/\/doi.org\/10.1007\/s10928-024-09910-1. Epub 2024 Apr 12","DOI":"10.1007\/s10928-024-09910-1"},{"issue":"3","key":"9989_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/psp4.12753","volume":"11","author":"K Lingineni","year":"2022","unstructured":"Lingineni K, Aggarwal V, Morales JF, Conrado DJ, Corey D, Vong C et al (2022) Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy. CPT Pharmacom Syst Pharma 11(3):318\u2013332","journal-title":"CPT Pharmacom Syst Pharma"},{"issue":"8","key":"9989_CR36","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2215\/CJN.11151012","volume":"8","author":"JL Moskowitz","year":"2013","unstructured":"Moskowitz JL, Piret SE, Lhotta K, Kitzler TM, Tashman AP, Velez E et al (2013) Association between genotype and phenotype in uromodulin-associated kidney disease. Clin J Am Soc Nephrol 8(8):1349\u20131357","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"9989_CR37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1523-1755.2003.00081.x","volume":"64","author":"AJ Bleyer","year":"2003","unstructured":"Bleyer AJ, Woodard AS, Shihabi Z, Sandhu J, Zhu H, Satko SG et al (2003) Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. Kidney Int 64(1):36\u201342","journal-title":"Kidney Int"},{"issue":"10","key":"9989_CR38","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.2215\/CJN.01220211","volume":"6","author":"G Boll\u00e9e","year":"2011","unstructured":"Boll\u00e9e G, Dahan K, Flamant M, Morini\u00e8re V, Pawtowski A, Heidet L et al (2011) Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol 6(10):2429\u20132438","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09989-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:17:23Z","timestamp":1776755843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09989-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9989"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09989-0","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The supplementary file2 has been replaced.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"41"}}